Pharmacogenetics and drug therapy in psychiatry - The role of the CYP2D6 polymorphism

Current Pharmaceutical Design

Volumn 13, Issue 2, 2007, Pages 241-250

  Vandel, P ^a   Talon, J M ^a   Haffen, E ^a   Sechter, D ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

CYP2D6; Metabolic polymorphism; Pharmacogenetics; Therapeutic implications

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2D6; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; LOXAPINE; MAPROTILINE; MIANSERIN; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PERPHENAZINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRIFLUPERIDOL; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; ZUCLOPENTHIXOL;

CLINICAL PRACTICE; DEPRESSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG TRANSFORMATION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PARKINSONISM; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOLOGICAL ASPECT; REVIEW; SCHIZOPHRENIA; SCREENING; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; TARDIVE DYSKINESIA;

ANIMALS; CYTOCHROME P-450 CYP2D6; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHIATRY;

EID: 33846134330     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313704     Document Type: Review

References (76)

1. Kalow WI. Drug metabolism enzymes. Pharmacogenetics in animals and man. Ann N Y Acad Sci 1968; 151(2): 694-8.
2. Kalow W, Inaba T. Genetic factors in hepatic drug oxidation. Prog Liver Dis 1976; 5: 246-58.
3. Baumann P, Jonzier-Perey M. GC and GC-MS procedures for simultaneous phenotyping with dextromethorphan and mephenytoin. Clin Chim Acta 1988; 171(2-3):211-22.
4. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1982; 7: 1-22.
5. Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. In: Pirmohamed M Ed; Review Series on Pharmacogenetics. Blackwell Science Ltd Br J Clin Pharmacol 2002; 53(2); 111-22.
6. Sjöqvist F. Polymorphisms in drug metabolism: implications for drug utilization. Biochem Soc Trans 1984; 12(1): 101-3.
7. Baker GB, Prior TI. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann Med 2002; 34: 537-43.
8. Baumann P, Eap CB. Enantiomeric antidepressant drugs should be considered on individual merit. Hum Psychopharmacol 2001; 16: S85-S92.
9. Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001; 21: 330-4.
10. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, et al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003; 13: 39-47.
11. Hindmarch I. The enantiomer debate: current status and future directions. Hum Psychopharmacol 2001; 16: S101-S104.
12. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998; 249: 838-43.
13. Cupp MJ, Tracy TS. Cytochrome P450: New nomenclature and clinical implications. Am Fam Physician 1998; 57: 107-16.
14. Glue P, Clement RP. Cytochrome P450 enzymes and drug metabolism - Basic concepts and methods of assessement. Cell Mol Neurobiol 1999; 19: 309-23.
15. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12: 1-51.
16. Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin pharmacol Ther 1992; 51: 12-17.
17. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003; 192(1): 23-32.
18. Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63.
19. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90: 11825-9.
20. Vandel S, Bertschy G, Baumann P, Bouquet S, Bonin B, Francois T, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995; 31: 347-53.
21. Bertschy G, Vandel S, Perault MC. A case of metabolic interaction: amitriptyline, fluoxetine, antitubercular agents. Therapie 1994; 49: 509-12.
22. Barnes J, Anderson LA, Phillipson JD. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53(5): 583-600.
23. Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2005; 78(4): 440-1.
24. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97(13): 7500-2.
25. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22(1): 46-54.
26. Izzo AA. Drug interactions with St John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42(3): 139-48.
27. Singh YN. Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 2005; 100(l-2): 108-13.
28. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb-drug interactions: a literature review. Drugs 2005; 65(9): 1239-82.
29. Alexanderson B, Evans DAP, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969; 4: 764-8.
30. Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz HU, Sjöqvist F. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980; 27: 1673-7.
31. Kalow W, Orton SV, Kadar D, Endrenyi L, Inaba T. Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.Can J Physiol Pharmacol 1980; 58(9): 1142-4.
32. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39: 533-7.
33. Hadidi HF, Cholerton S, Monkman SC, Armstrong M, Irshaid YM, Rawashdeh NM et al. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians. Pharmacogenetics 1994; 4(3): 159-61.
34. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51(4): 388-97.
35. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38(4): 402-8.
36. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32(4): 504-7.
37. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American blacks versus whites. Clin Pharmacol Ther 1991; 50: 308-13.
38. Dandara C, Masimirembwa CM, Magimba A, Sayi J, Kaaya S, Sommers DK, et al. Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients. Eur J Clin Pharmacol 2001; 57: 11-7.
39. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-59.
40. Potkin SG, Shen Y, Pardes H, Phelps BH, Zhou D, Shu L, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984;12(2):167-72.
41. Rudorfer MV, Lane EA, Chang WH, Zhang MD, Potter WZ. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984; 17(4): 433-40.
42. Liu P. Clinical psychopharmacology in China: the last decade. Psychiatry Clin Neurosci 1998; 52 Suppl: 190-2.
43. Coutts RT, Urichuk L.J. Polymorphic cytochromes P450 and drugs used in Psychiatry. Cell Mol Neurobiol 1999; 19: 325-54.
44. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-92.
45. Baumann P, Broly F, Kosel K Eap CB. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2D6 genotyping. Pharmacopsychiatry 1998; 31: 72.
46. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P4502D6 variants in a caucasian population. Allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95.
47. Agúndez JA, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995a; 57: 265-9.
48. McLellan RA, Oscarson M, Seidegard J, Evans DA, Ingelman-Sundberg M. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7(3): 187-91.
49. Wilcox RA, Owen H. Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anaesthetist. Anaesth Intensive Care 2000; 28(6): 611-9.
50. Dahlén P, Frengell C, Dahl ML, Sjöqvist F. Quick onset of severe abdominal pain after codeine in a ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19:543-4.
51. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 56: 1667-71.
52. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118-21.
53. Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 2000; 56: 679-83.
54. Vandel P, Haffen E, Vandel S, Bonin B, Nezelof S, Sechter D, et al. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol 1999; 55: 659-65.
55. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-52.
56. Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphim on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20: 246-51.
57. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-70.
58. Dahl ML, Sjöqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 2000; 22: 114-7.
59. Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther 1999; 24: 7-16.
60. Fang J, Gorrod JW. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 1999; 19:491-510.
61. Spina E, Steiner E, Dumont E, Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators. Psychopharmacol Ser 1989; 7:201-205.
62. Pickar D. Pharmacogenomics of psychiatric drug treatment. Psychiatr Clin North Am 2003; 26(2): 303-21.
63. Ozdemir V, Basile VS, Masellis M, Kennedy JL. Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes. J Biochem Biophys Methods 2001; 47: 151-7.
64. Segman RH, Heresco-Levy U, Finkel B, Inbar R, Neeman T, Schlafman M, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology 2000; 152: 408-13.
65. Bondy B, Zill P. Psychopharmacogenetics - a challenge for pharmacotherapy in psychiatry. World J Biol Psychiatry 2001; 2: 178-83
66. Catalano M. Functionally gene-linked polymorphic regions and genetically controlled neurotransmitters metabolism. Eur Neuropsychopharmacol 2001; 11: 431-9.
67. Staddon S, Arranz MJ, Mancana D, Mata I, Kerwin RW. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacol 2002; 162: 18-23.
68. Arranz MJ, Collier D, Kerwin RW. Pharmacogenetics for the individualization of psychiatric treatment. Am J Pharmacogenomics 2001; 1: 3-10.
69. Kirchheiner J, Bertilsson L, Bruus H, Wolff A, Roots I, Bauer M. Individualized medicine-implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 2003; 36(Suppl 3): S235-43.
70. Serretti A, Lilli R, Smeraldi E. Pharmacogenetics in affective disorders. Eur J Pharmacol 2002; 438: 117-28.
71. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med 2001; 250: 186-200.
72. Meisel C, Roots I, Cascorbi I, Brinkmann U, Brockmoller J. How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport. Clin Chem Lab Med 2000; 38: 869-76.
73. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part 1. J Clin Psychopharmacol 1996; 16: 273-85.
74. Lane RM. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11 suppl 5: 31-61.
75. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1997; 32(Suppl 1): 1-21.
76. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clin Pharm Ther 1998; 23: 403-16.